We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

July 7, 2022

Five Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community
&

Over the past month, our HealthXL community members discussed the value of DTx-generated RWD, DTx Reimbursement in the US-Value- Based Contracting (VBC) Basics, and Remote Patient Monitoring programs for Pharma, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

#1 On DTx-generated RWD: What is the Value for Pharma?: What pharma does with real world data (RWD) and real world evidence (RWE) depends on the use case and the team. Commercial teams will want the output, whereas, marketing teams and R&D will want the raw data. Pharma should have clearly defined objectives and specific data points to target, to enable the digital company to collect and analyze data more rigorously, resulting in higher output quality. With tight regulation and restrictive models, pharma may struggle to incorporate RWD and RWE, processes may need to be adapted, which needs to be in hand with changes in the regulatory bodies. As business models develop and processes are updated, RWD and RWE will become increasingly valuable. 

#2 On sustainable business models for DTx in the US: In digital health, the best business model depends on the product. For prescription DTx, reimbursement from a payer organization is a must, taking into account the size of patient population, as well as the level of clinical and economic evidence available. Smaller patient population DTx companies might target healthcare providers, using bundled payments in treating these smaller patient populations. Hybrid models can use their user base to extract data to expand to other markets. Partnering with pharma companies that can add the DTx product as part of their drug label may make regulation and negotiations with payers easier. 

#3 On what’s in Remote Patient Monitoring programs for Pharma: For Pharma, companies don’t get paid to decrease overall healthcare costs, which means the commercial imperative for Remote Patient Monitoring (RPM) must come from another avenue. Outside of use in clinical trials, the commercial merits of integrating RPM into day-to-day care are tricky. To show value, an RPM must demonstrate the potential to cut costs, enable new revenue lines or create revenue protecting data in an area such as adherence. For RPM to have an impact, it must successfully integrate both from a patient and healthcare perspective, and be effortless for the patient to ensure compliance. 

#4 On DTx Reimbursement in the US-Value- Based Contracting Basics: Value-based contracts (VBCs) can be an opportunity to meet the interests of a number of health ecosystem stakeholders. They can be linked to clinical and/or financial outcomes, including adherence, prevalence of events, total costs of care, capitation, among others, and can be structured to solve many different commercial and access objectives. DTx will likely accelerate the US VBC environment due to: 24/7 therapeutic usage understanding, ease of access to other product specific patient and physician reported data; payer perception of need to de-risk clinical, coverage decisions more so than drugs, and PDT/DTx having more latitude in contracting and pricing than biopharma. 

#5 On how to design a clinical trial for your digital health product: Proving clinical efficacy through clinical trials is one of the biggest challenges for digital health companies. Trials need developers and clinical teams to work together to create studies with better results. Real world data and evidence (RWD and RWE) in trials can have many benefits, including cost savings when designed to work in parallel with randomized controlled clinical trials (RCTs). RCTs are difficult to implement as they need a comparator which is difficult in the digital health space. In the absence of a comparator,  the goal is to compare to the current standard of care whether it is a drug or another treatment. Patient recruitment can still be successful when the eligibility parameters are more relaxed, but patients need meaningful endpoints and effective communications. Furthermore, the industry needs to work on digital health literacy to get patient, caregiver and physician buy-in for these trials. 

Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Community for access to polls and summaries from all of our meetings. 

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Standing Out from the Crowd in Economic Recession

14th February @ 10:45AM EDT

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Endpoints and Control Arms in Trials for DTx

15th February @ 10:45AM EDT

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

The Role of the Consumer Experience in DTx

15th February @ 10:45AM EDT

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Incorporating Extended Reality (XR) in Physician's’ Daily Work

28th February @ 10:45AM EDT

The healthcare industry is undergoing a digital transformation and extended reality (XR) technologies such as virtual reality (VR) and augmented reality (AR) are expected to play a significant role in this change in the next few years. Apply now to join this Masterclass led by Nemanja Kovačev, MedTech Expert at HTEC Group.

Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group
Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Health Meeting
7th February @ 10:45AM EDT

Product Differentiation for Digital Health Solutions in the Cardiometabolic Disease Area

In the past few years, digital health solutions have proven to be helpful in preventing and managing cardiometabolic diseases remotely, leading to better  health outcomes and less hospitalizations, emergency visits, and in-office visits.

Jenn Roberts
Featuring
Jenn Roberts
Vice President Employer Health Strategy, Hello Heart
Telemedicine & Virtual Care Delivery
9th February @ 10:45AM EDT

Business Opportunities for Digital Health in Autoimmune Conditions: Upcoming Blockbuster Drugs

Millions of people worldwide suffer from autoimmune conditions such as rheumatoid arthritis (RA), psoriasis, lupus, Crohn's disease, multiple sclerosis, atopic dermatitis, to name a few. Join this meeting to deep dive into this topic in the Immunology Meeting Series. Seats are limited so apply now to secure your place.

Erik Janssen
Featuring
Erik Janssen
VP Global Digital Care Transformation Immunology, UCB
Digital Therapeutics (DTx)
14th February @ 10:45AM EDT

Masterclass: Standing Out from the Crowd in Economic Recession

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Jeremy Sohn
Featuring
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
15th February @ 10:45AM EDT

Masterclass: Endpoints and Control Arms in Trials for DTx

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Acacia Parks
Featuring
Acacia Parks
Chief Science Officer, Twill

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.